Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

Journal of the American Geriatrics Society

Volumn 51, Issue 7, 2003, Pages 937-944

  Geldmacher, David S ^a,b   Provenzano, George ^c   McRae, Thomas ^d   Mastey, Vera ^d   Ieni, John R ^e  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

^d PFIZER INC   (United States)

^e EISAI INC   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Donepezil; Nursing home placement

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SOCIAL ASPECT; SURVIVAL;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDANS; INSTITUTIONALIZATION; MALE; NURSING HOMES; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0037707465     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2389.2003.51306.x     Document Type: Article

References (29)

1. Galasko D, Edland SD, Morris JC et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years. Neurology 1995;45: 1451-1455.
2. Winblad B, Wimo A. Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord 1999;13 (Suppl. 2):S9-S19.
3. Teri L. Behavior and caregiver burden: Behavioral problems in patients with Alzheimer disease and its association with caregiver distress. Alzheimer Dis Assoc Disord 1997;11 (Suppl. 4):S35-S38.
4. Hope T, Keene J, Gedling K et al. Predictors of institutionalization for people with dementia living at home with a carer. Int J Geriatr Psychiatry 1998;13: 682-690.
5. Heyman A, Peterson B, Fillenbaum G et al. Predictors of time to institutionalization of patients with Alzheimer's disease. The CERAD Experience, Part XVII. Neurology 1997;48:1304-1309.
6. Severson MA, Smith GE, Tangalos EG et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc 1994;42:181-185.
7. Chenoweth B, Spencer B. Dementia. The experience of family caregivers. Gerontologist 1986;26:267-272.
8. Cohen CA, Gold DP, Shulman KI et al. Factors determining the decision to institutionalize dementing individuals: A prospective study. Gerontologist 1993;33:714-720.
9. Knopman DS, Kitto J, Deinard S et al. Longitudinal study of death and institutionalization in patients with primary degenerative dementia. J Am Geriatr Soc 1988;36:108-112.
10. Steele C, Rovner B, Chase GA et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147: 1049-1051.
11. Lieberman MA, Kramer JH. Factors affecting decisions to institutionalize demented elderly. Gerontologist 1991;31:371-374.
12. Mittelman MS, Ferris SH, Shulman E et al. A family intervention to delay nursing home placement of patients with Alzheimer disease: A randomized controlled trial. JAMA 1996;276:1725-1731.
13. Karlawish JHT, Klocinski JL, Merz J et al. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 2000;55:1008-1014.
14. Ernst RL, Hay JW. Economic research on Alzheimer disease. A review of the literature. Alzheimer Dis Assoc Disord 1997;11 (Suppl. 6):135-145.
15. Leon J, Cheng CK, Neumann PJ. Alzheimer's disease care. Costs and potential savings. Health Aff 1998;17:206-216.
16. Johnson N, Davis T, Bosanquet N. The epidemic of Alzheimer's disease. How can we manage the costs? Pharmacoeconomics 2000;18:215-223.
17. Trabucchi M. An economic perspective on Alzheimer's disease. J Geriatr Psychiatry Neurol 1999;12:29-38.
18. Rogers SL, Friedhoff LT. Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293-303.
19. Rogers SL, Doody RS, Mohs RC et al. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-1031.
20. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-bind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-145.
21. Knopman D, Schneider L, Davis K et al. Long-term tacrine (Cognex) treatment. Effects on nursing home placement and mortality. Neurology 1996;47: 166-177.
22. Rogers SL, Doody RS, Pratt RD et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10:195-203.
23. Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-433.
24. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57:481-488.
25. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in AD patients. Neurology 2001;57:489-495.
26. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57:613-620.
27. Lopez OL, Becker JT, Wisniewski S et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
28. Doody RS, Stevens JC, Beck C et al. Practice parameter. Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-1166.
29. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatr Soc 2002;50:35-40.